Argenx
ARGX
#555
Rank
NZ$63.83 B
Marketcap
$1,001
Share price
-3.91%
Change (1 day)
60.72%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Operating Margin for Argenx (ARGX)

Operating Margin as of March 2025 (TTM): -24.83%

According to Argenx 's latest financial reports and stock price the company's current Operating Margin is -24.83%. At the end of 2023 the company had an Operating Margin of -24.83%.

Operating Margin history for Argenx from 2013 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
2023-24.83%-86.02%
2022-177.56%120.88%
2021-80.39%-94.52%
2020-1,467.77%554.64%
2019-224.21%-26.85%
2018-306.52%306.2%
2017-75.46%-48.06%
2016-145.27%-34.97%
2015-223.40%-18.64%
2014-274.60%19.9%
2013-229.03%-61.01%
2012-587.40%90.71%
2011-308.00%

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.